A Safety, Tolerability, and Immunogenicity Study of mRNA-1345 and mRNA-1365 in Participants Aged 5 Months to <24 Months
A Phase 1, Randomized, Observer-blind, Placebo-controlled, Age De-escalation Study of the Safety, Tolerability, and Immunogenicity of mRNA-1345 and mRNA-1365 in Participants Aged 5 Months to <24 Months
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 1
Contacts and Locations
Study Contact
Study Contact
- Name: Moderna Clinical Trials Support Center
- Phone Number: 1-877-777-7187
- Email: clinicaltrials@modernatx.com
Study Locations
-
-
-
Panama City, Panama, 0801
- CEVAXIN Avenida Mexico
-
Panama City, Panama
- CEVAXIN 24 de Diciembre
-
-
Chiriquí Province
-
David, Chiriquí Province, Panama, 0401
- CEVAXIN David
-
-
Panamá Oeste Province
-
La Chorrera, Panamá Oeste Province, Panama
- CEVAXIN Chorrera
-
-
-
-
-
Norwich, United Kingdom, NR4 7UY
- Norfolk and Norwich University Hospitals
-
-
-
-
California
-
Los Angeles, California, United States, 90057
- Matrix Clinical Research
-
-
District of Columbia
-
Washington D.C., District of Columbia, United States, 20016
- Meridian Clinical Research
-
-
Illinois
-
Melrose Park, Illinois, United States, 60160
- DM Clinical Research- River Forest
-
-
Louisiana
-
Lafayette, Louisiana, United States, 70508
- MedPharmics - Platinum - PPDS
-
-
North Carolina
-
Durham, North Carolina, United States, 27703
- Duke Vaccine and Trials Unit
-
-
Rhode Island
-
Providence, Rhode Island, United States, 02886
- Velocity Clinical Research - Providence
-
-
South Carolina
-
North Charleston, South Carolina, United States, 29406-9170
- Palmetto Pediatrics, PA
-
-
Tennessee
-
Nashville, Tennessee, United States, 37232
- Vanderbilt Vaccine Research Program
-
-
Texas
-
Houston, Texas, United States, 77087
- Pediatric Associates
-
Houston, Texas, United States, 77065
- CyFair
-
Plano, Texas, United States, 75024
- Village Pediatrics
-
Richmond, Texas, United States, 77469
- Pediatric Center
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- The participant is 8 months to <24 months (Part A), 5 months to <8 months (Part B), or 8 months to <12 months (Part C) of age at the time of randomization (Day 1/Baseline visit), who is in good general health, in the opinion of the Investigator, based on review of medical history and screening physical examination.
- In the Investigator's opinion, the parent(s)/ legally authorized representative (LAR)(s) understand and are willing and physically able to comply with protocol-mandated follow up, including all procedures, and provide written informed consent.
- The participant is growing normally for age in the opinion of the site clinician in the months prior to enrollment.
- The participant was born at full-term (≥37 weeks gestation) with a minimum birth weight of 2.5 kilograms (kg).
- For Part C Cohort 7: participant must have received nirsevimab ≥6 months prior to Day 1 Visit.
- For Part C Cohort 8: participant was eligible at any time since birth, according to national guidelines, to receive nirsevimab prior to Day 1 Visit but did not do so.
Exclusion Criteria:
- Has a known history of symptomatic RSV (Part A: within 3 months; Part B and Part C: since birth) or hMPV infection (Part A: within 3 months; Part B: since birth) prior to administration of the first dose of investigational product (IP) or has a known close contact with anyone with laboratory-confirmed RSV (Parts A, B, and C) or hMPV infection (Parts A or B) within 14 days prior to administration of the first dose of IP.
- Is acutely ill or febrile 24 hours prior to or at the screening visit. Fever is defined as a body temperature ≥38.0°Celsius/≥100.4°Fahrenheit. Participants who meet this criterion may have visits rescheduled within the relevant study visit windows.
- Has previously been administered an investigational or approved vaccine for prevention of RSV (Parts A, B, and C) or hMPV (Parts A and B) infection or if the participant's mother received an investigational or approved vaccine for the prevention of RSV (Parts A, B, and C) or hMPV (Parts A and B) infection during pregnancy.
- Has received investigational or approved agents for prophylaxis against RSV or hMPV (for example, monoclonal antibodies) or is intending to receive these during the course of the study. For Part C (Cohort 7 only), use of nirsevimab ≥6 months before Day 1 Visit is allowed.
- Has a known hypersensitivity to a component of the vaccine or its excipients. Hypersensitivity includes, but is not limited to, anaphylaxis or immediate allergic reaction of any severity to a previous dose of an mRNA vaccine or any of its components (including polyethylene glycol or immediate allergic reaction of any severity to polysorbate).
- Has a medical condition that, according to the Investigator's judgment, may pose additional risk as a result of participation, interfere with safety assessments, or interfere with interpretation of results.
Note: Other protocol-defined inclusion/exclusion criteria apply.
Inclusion Criteria:
- For Part B Extension: participants enrolled and dosed in Part B (Cohorts 3 to 6); either reached the end of study of the Main Study or were dosed and subsequently discontinued from the Main Study. This includes participants who were lost to follow-up, if they can be re-engaged.
- For Part B Extension: participant's parent(s)/LAR(s) has provided written informed consent for participation in Part B of the Main Study and the Part B Extension.
Exclusion Criteria:
• For Part B Extension, there are no specific exclusion criteria.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Part A: mRNA-1345, Dose 1 (Age Group: 8 to <24 months)
Participants will receive mRNA-1345 vaccine by intramuscular (IM) injection on Days 1, 57 and 113.
|
Sterile liquid for injection
|
|
Experimental: Part A: mRNA-1365, Dose 1 (Age Group: 8 to <24 months)
Participants will receive mRNA-1365 vaccine by IM injection on Days 1, 57 and 113.
|
Sterile liquid for injection
|
|
Placebo Comparator: Part A: Placebo (Age Group: 8 to <24 months)
Participants will receive mRNA-1345/ mRNA-1365 vaccine matching placebo by IM injection on Days 1, 57 and 113.
In countries where applicable, participants may receive Nimenrix instead of placebo on Day 113.
|
0.9% sodium chloride (normal saline) solution for injection
Solution for injection
|
|
Experimental: Part B: mRNA-1345, Dose 2 (Age Group: 5 to <8 months)
Participants will receive mRNA-1345 by IM injection on Days 1, 57 and 113.
|
Sterile liquid for injection
|
|
Experimental: Part B: mRNA-1365, Dose 2 (Age Group: 5 to <8 months)
Participants will receive mRNA-1365 by IM injection on Days 1, 57 and 113.
|
Sterile liquid for injection
|
|
Experimental: Part B: mRNA-1345 Dose 1 (Age Group: 5 to <8 months)
Participants will receive mRNA-1345 by IM injection on Days 1, 57 and 113.
|
Sterile liquid for injection
|
|
Experimental: Part B: mRNA-1365 Dose 1 (Age Group: 5 to <8 months)
Participants will receive mRNA-1365 by IM injection on Days 1, 57 and 113.
|
Sterile liquid for injection
|
|
Placebo Comparator: Part B: Placebo (Age Group: 5 to <8 months)
Participants will receive mRNA-1345/ mRNA-1365 vaccine matching placebo by IM injection on Days 1, 57 and 113.
In countries where applicable, participants may receive Nimenrix instead of placebo on Day 113.
|
0.9% sodium chloride (normal saline) solution for injection
Solution for injection
|
|
No Intervention: Part B Extension: mRNA-1345, Dose 2 (Age Group: 5 to <8 months)
Participants will have the option to re-enrol in the Part B extension period.
|
|
|
No Intervention: Part B Extension: mRNA-1365, Dose 2 (Age Group: 5 to <8 months)
Participants will have the option to re-enrol in the Part B extension period.
|
|
|
No Intervention: Part B Extension: mRNA-1345 Dose 1 (Age Group: 5 to <8 months)
Participants will have the option to re-enrol in the Part B extension period.
|
|
|
No Intervention: Part B Extension: mRNA-1365 Dose 1 (Age Group: 5 to <8 months)
Participants will have the option to re-enrol in the Part B extension period.
|
|
|
No Intervention: Part B Extension : Placebo (Age Group: 5 to <8 months)
Participants will have the option to re-enrol in the Part B extension period.
|
|
|
Experimental: Part C: mRNA-1345 Dose 1 (Age Group 8 to <12 months exposed to nirsevimab)
Participants who have been previously exposed to nirsevimab will receive mRNA 1345 by IM injection on Days 1, 57, and 113.
|
Sterile liquid for injection
|
|
Experimental: Part C: mRNA-1345 Dose 1 (Age Group 8 to <12 months not exposed to nirsevimab)
Participants who have not been previously exposed to nirsevimab will receive mRNA 1345 by IM injection on Days 1, 57, and 113.
|
Sterile liquid for injection
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Main Study: Number of Participants with Solicited Local and Systemic Adverse Reactions (ARs)
Time Frame: Up to Day 120 (7 days after each injection)
|
Up to Day 120 (7 days after each injection)
|
|
Main Study: Number of Participants with Unsolicited Adverse Events (AEs)
Time Frame: Up to Day 141 (28 days after each injection)
|
Up to Day 141 (28 days after each injection)
|
|
Main Study: Number of Participants with Medically-Attended Adverse Events (MAAEs)
Time Frame: Day 1 through Day 730
|
Day 1 through Day 730
|
|
Main Study: Number of Participants with Adverse Event of Special Interests (AESIs), Serious Adverse Events (SAEs) and Adverse Events Leading to Discontinuation
Time Frame: Day 1 through Day 730
|
Day 1 through Day 730
|
|
Part B Extension: Number of Participants with MAAEs, AESIs and SAEs
Time Frame: Day 1 of the Extension to end of study (EoS) (up to 3 years)
|
Day 1 of the Extension to end of study (EoS) (up to 3 years)
|
|
Part B Extension: Number of Participants with Lower Respiratory Tract Illness (LRTI), Severe LRTI, Very Severe LRTI, and Hospitalizations Associated with RSV or hMPV
Time Frame: Day 1 of the Extension to EoS (up to 3 years)
|
Day 1 of the Extension to EoS (up to 3 years)
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Main Study: Number of Participants with Respiratory tract Illness (RTI), LRTI, Severe LRTI, Very Severe LRTI, and Hospitalizations Associated with RSV or hMPV
Time Frame: Day 1 through Day 730
|
Day 1 through Day 730
|
|
Main Study (Parts A and B): Geometric Mean Titer (GMT) of Serum RSV and hMPV Neutralizing Antibodies
Time Frame: Baseline up to Month 12
|
Baseline up to Month 12
|
|
Main Study (Part C): GMT of Serum RSV Neutralizing Antibodies
Time Frame: Baseline up to Month 12
|
Baseline up to Month 12
|
|
Main Study (Parts A and B): Geometric Mean Concentration (GMC) of Serum RSV F- and hMPV F-Binding Antibodies
Time Frame: Baseline up to Month 12
|
Baseline up to Month 12
|
|
Main Study (Part C): GMC of Serum RSV F-Binding Antibodies
Time Frame: Baseline up to Month 12
|
Baseline up to Month 12
|
|
Main Study: Geometric Mean Fold-Rise (GMFR) of Postbaseline/baseline Neutralizing Antibody Titers and Binding Antibody
Time Frame: Month 12
|
Month 12
|
|
Main Study: Number of Participants with Vaccine-specific T-cell Responses Measured by Flow Cytometry
Time Frame: Baseline up to Month 12
|
Baseline up to Month 12
|
|
Part B Extension: Geometric Mean Titer (GMT) of Serum RSV and hMPV Neutralizing Antibodies
Time Frame: Day 1 of the Extension up to EoS (up to 3 years)
|
Day 1 of the Extension up to EoS (up to 3 years)
|
|
Part B Extension: Geometric Mean Concentration (GMC) of Serum RSV F- and hMPV F-Binding Antibodies
Time Frame: Day 1 of the Extension up to EoS (up to 3 years)
|
Day 1 of the Extension up to EoS (up to 3 years)
|
|
Part B Extension: Geometric Mean Fold-Rise (GMFR) of Postbaseline/baseline Neutralizing Antibody Titers and Binding Antibody
Time Frame: Day 1 of the Extension up to EoS (up to 3 years)
|
Day 1 of the Extension up to EoS (up to 3 years)
|
|
Part B Extension: Number of Participants with Vaccine-specific T-cell Responses Measured by Flow Cytometry
Time Frame: Day 1 of the Extension up to EoS (up to 3 years)
|
Day 1 of the Extension up to EoS (up to 3 years)
|
Collaborators and Investigators
Sponsor
Sponsor
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- mRNA-1365-P101
- 2022-502022-41 (EudraCT Number)
- 2022-502022-41-00 (Other Identifier: EU CT Number)
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.